BusinessKura Oncology Development Candidate KO-539 Shows Robust Preclinical Anti-Tumor Activity in NPM1- and DNMT3A-Mutant AMLBy Nasdaq OMXOct 28, 2017, 4:30 PM UTC
BusinessKura Oncology Lead Candidate Tipifarnib Shows Durable Anti-Tumor Activity in HRAS Mutant Head and Neck Cancer in AACR-NCI-EORTC UpdateBy Nasdaq OMXOct 27, 2017, 2:50 PM UTC
BusinessKura Oncology Announces Late-Breaking Presentations for Tipifarnib in HRAS Mutant Squamous Head and Neck Cancer and for KO-539 in AML at Upcoming AACR-NCI-EORTC International ConferenceBy Nasdaq OMXOct 16, 2017, 11:30 AM UTC
BusinessKura Oncology Announces Positive Phase 2 Study for Tipifarnib in HRAS Mutant Head and Neck CancerBy Nasdaq OMXSep 7, 2017, 8:05 PM UTC
BusinessKura Oncology to Participate in Citi’s 12th Annual Biotech ConferenceBy Nasdaq OMXAug 29, 2017, 11:30 AM UTC
BusinessKura Oncology Announces Commencement of Public Offering of Common StockBy Nasdaq OMXAug 9, 2017, 8:17 PM UTC
BusinessKura Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Tipifarnib Phase 2 StudyBy Nasdaq OMXAug 7, 2017, 8:06 PM UTC
BusinessKura Oncology Establishes Collaboration with Foundation Medicine to Support Tipifarnib Development in HRAS Mutant Head and Neck CancerBy Nasdaq OMXJul 13, 2017, 11:30 AM UTC
